JR-141
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis II
Conditions
Mucopolysaccharidosis II
Trial Timeline
Mar 30, 2017 → Oct 4, 2017
NCT ID
NCT03128593About JR-141
JR-141 is a phase 1/2 stage product being developed by JCR Pharmaceuticals for Mucopolysaccharidosis II. The current trial status is completed. This product is registered under clinical trial identifier NCT03128593. Target conditions include Mucopolysaccharidosis II.
What happened to similar drugs?
5 of 15 similar drugs in Mucopolysaccharidosis II were approved
Approved (5) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05594992 | Phase 3 | Recruiting |
| NCT04348136 | Phase 2/3 | Active |
| NCT03708965 | Phase 2 | Active |
| NCT03568175 | Phase 2/3 | Completed |
| NCT03128593 | Phase 1/2 | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis II